NAD boosters for memory: what controlled NR trials actually show

A brain-health claim needs a cognitive outcome

If a product promises better memory, I would look first for a controlled human study that actually measured cognition. A blood NAD result, a brain-image finding and a memory-test result can all be scientifically interesting while answering different questions. This synthesis brings three randomized oral nicotinamide riboside (NR) trials into one view. It is a focused comparison, not an exhaustive systematic review or a treatment recommendation.

The practical finding is restrained: the studies discussed here do not establish NR as a way to improve memory in the selected participants over their study periods. They also do not test the compounded NAD+ injection marketed by a telehealth service. Start with the ingredient and format guide if those two offers have begun to sound interchangeable. The same pathway is not the same intervention.

An early pilot separated blood NAD from cognitive performance

Orr and colleagues randomized 20 older adults with mild cognitive impairment in a 10-week placebo-controlled NR pilot. Blood NAD+ rose, while the paper describes cognitive performance as stable over the study. Tolerability was a central aim; a small pilot with stable cognitive measures should not be rewritten as a demonstrated memory treatment. ^[1]

That is a useful starting point for reading a supplement advertisement. Ask whether the highlighted number is the number you care about. If the headline shows a blood change, the next question is whether participants also improved on an appropriate cognitive test compared with placebo. Keep both answers visible. A biochemical response can justify more research without settling a consumer claim.

The biomarker result that can overshadow a negative cognitive result

In the Wu trial, 46 people with subjective cognitive decline or mild cognitive impairment were randomized; 37 completed the trial. After eight weeks of NR, the between-group comparison found a favorable difference in plasma pTau217, an Alzheimer-related biomarker. It found no significant between-group differences in the primary RBANS cognitive measure or digital cognitive scores. Those results belong together. ^[2]

I would not translate the biomarker result into a percentage improvement in memory, a diagnosis or proof of dementia prevention. The paper leaves room for future investigation of pathological processes. It does not supply the missing clinical benefit. Our guide to markers and benefits explains why a precise laboratory percentage can still leave a very ordinary question unanswered: did people think or remember better?

A later trial leaves the cognitive question open too

A 12-week phase-II randomized placebo-controlled pilot in adults with amnestic mild cognitive impairment reported 42 completers. NR increased blood NAD+ about twofold, but cognitive function, the primary outcome, did not improve; neither did total cerebral blood flow or blood pressure. Exploratory regional blood-flow findings were presented as a reason for further study. ^[3]

Read the word exploratory as part of the finding. A regional signal is not automatically a benefit in everyday memory, and a promising future study is not a result already available today. This trial also illustrates why “raises NAD” and “works for cognition” should occupy separate columns in a comparison. One can be observed while the other remains unestablished.

Three studies, three boundaries to keep visible

What the pattern means, and what it cannot mean

The repeated separation between biochemical signals and cognitive outcomes is the most useful consumer insight here. It makes a blood-NAD graph insufficient evidence for a memory promise. That is a judgment about what a claim requires, rather than a claim that every future NR study must fail. Small samples and short follow-up leave uncertainty, including whether a different population, intervention or duration could produce a different result.

Nor should the trials be pooled casually into one apparent success rate. A subjective complaint, a diagnosis of mild cognitive impairment and amnestic impairment are not identical recruitment criteria. Study completion, analysis approach and the cognitive instrument matter too. The study claim reader gives each paper its own worksheet so those differences remain visible. Our individual reports on the early pilot, pTau217 trial and phase-II study provide additional context.

How I would use this before choosing a product

First write the claim in plain language. “This product supports NAD metabolism” and “this product will improve my memory” are different statements. Request a source matching the second statement if that is why you are considering the purchase. Ask which formulation, route, participants and endpoint it tested. A citation to oral NR should not quietly become evidence for a home NAD+ injection, an NMN combination or a liposomal blend.

Second, evaluate the commercial offer separately. The Tru Niagen review concerns an NR supplement purchase. The welludr. review and iThriveMD review concern clinical injection services. Those reviews can help with labels, support and commitments; they do not turn any seller into a proven memory treatment. A product can be easy to buy while the outcome that interests you remains uncertain.

Finally, avoid choosing a prepaid duration to match an imagined deadline for improvement. A trial lasting eight or twelve weeks does not mean a commercial product is expected to work by its next renewal. Use the subscription commitment comparator to understand the financial decision, and discuss personal cognitive concerns with a qualified clinician. Research interpretation and a personal evaluation have different jobs.